PMID- 32111764
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 34
IP  - 2
DP  - 2020 Mar-Apr
TI  - PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: 
      Clinicopathological Analysis in Women Younger than 40 Years Old.
PG  - 639-647
LID - 10.21873/invivo.11818 [doi]
AB  - BACKGROUND/AIM: To evaluate the association between programmed cell death ligand 
      1 (PD-L1) expression on both tumor cells (TC) and inflammatory cells (IC), tumor 
      infiltrating lymphocytes (TILs), CD3(+) and CD8(+) lymphocytes and other 
      clinicopathological parameters in primary infiltrative breast cancer (IBC) of 
      young women, a population shown to have a worse prognosis. MATERIALS AND METHODS: 
      A retrospective study was performed collecting data from patients younger than 40 
      years old. Forty-five young women with IBC were included. Whole tissue sections 
      were used to evaluate all parameters. RESULTS: Twenty percent (20%) of cases 
      showed PD-L1 expression by tumor cells (PDL1TC) and 44.4% showed PD-L1 expression 
      by immune cells (PDL1IC). Furthermore, 28.88% revealed high stromal TILs. PDL1TC 
      and PDL1IC expression were significantly associated with tumor diameter and 
      expression of estrogen (ER) and progesterone (PR) receptors and Ki67. PDL1TC 
      expression was also associated with grade. High TILs were associated with tumor 
      diameter, ER and Ki67 expression. PDL1TC, PDL1IC expression and TILs were 
      associated with the density of CD3(+) and CD8(+) lymphocytes. CONCLUSION: Our 
      results are similar to those of other age groups, as reported in the literature.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Evangelou, Zoi
AU  - Evangelou Z
AD  - Department of Pathology, University Hospital of Ioannina, Ioannina, Greece 
      zoe_evag@yahoo.com.
FAU - Papoudou-Bai, Alexandra
AU  - Papoudou-Bai A
AD  - Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.
FAU - Karpathiou, Georgia
AU  - Karpathiou G
AD  - Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, 
      France.
FAU - Kourea, Helen
AU  - Kourea H
AD  - Department of Pathology, University Hospital of Patras, Patras, Greece.
FAU - Kamina, Sevasti
AU  - Kamina S
AD  - Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.
FAU - Goussia, Anna
AU  - Goussia A
AD  - Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.
FAU - Harissis, Haralambos
AU  - Harissis H
AD  - Department of Surgery, Breast Unit, University Hospital of Ioannina, Ioannina, 
      Greece.
FAU - Peschos, Dimitrios
AU  - Peschos D
AD  - Department of Physiology, Faculty of Medicine, University of Ioannina, Ioannina, 
      Greece.
FAU - Batistatou, Anna
AU  - Batistatou A
AD  - Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD3 Complex)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (MKI67 protein, human)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Adult
MH  - B7-H1 Antigen/*biosynthesis
MH  - Biomarkers, Tumor/biosynthesis
MH  - Breast Neoplasms/*metabolism/pathology
MH  - CD3 Complex/biosynthesis
MH  - CD8-Positive T-Lymphocytes/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods/statistics & numerical data
MH  - Ki-67 Antigen/biosynthesis
MH  - Lymphocytes, Tumor-Infiltrating/*metabolism
MH  - Prognosis
MH  - Receptors, Estrogen/biosynthesis
MH  - Receptors, Progesterone/biosynthesis
MH  - Retrospective Studies
PMC - PMC7157900
OTO - NOTNLM
OT  - Breast cancer
OT  - PD-L1
OT  - TILs
OT  - young women
COIS- All Authors declare that they have no conflicts of interest.
EDAT- 2020/03/01 06:00
MHDA- 2020/11/24 06:00
PMCR- 2020/03/03
CRDT- 2020/03/01 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2019/12/17 00:00 [revised]
PHST- 2020/01/08 00:00 [accepted]
PHST- 2020/03/01 06:00 [entrez]
PHST- 2020/03/01 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/03/03 00:00 [pmc-release]
AID - 34/2/639 [pii]
AID - 10.21873/invivo.11818 [doi]
PST - ppublish
SO  - In Vivo. 2020 Mar-Apr;34(2):639-647. doi: 10.21873/invivo.11818.